Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
O96015
UPID:
DNAL4_HUMAN
Alternative names:
-
Alternative UPACC:
O96015; Q6FGB2; Q6FGD0
Background:
Dynein axonemal light chain 4 is a pivotal force-generating protein of respiratory cilia, driving movement towards the minus ends of microtubules with its ATPase activity. This protein plays a crucial role in the proper functioning of ciliary structures, essential for cellular processes and movement.
Therapeutic significance:
Mirror movements 3, a disorder characterized by involuntary mirroring of voluntary movements, is linked to variants affecting Dynein axonemal light chain 4. Understanding the role of this protein could open doors to potential therapeutic strategies for treating or managing this condition.